Fig. 5.

CDD-787 and CDD-956 maintain BD1 selectivity, potency, and activity in cellular models. (A) NanoBRET assays of compounds CDD-786, CDD-787, CDD-956, and CDD-2107. (B) Viability IC₅₀ of CDD compounds on 4 AML cell lines after 72 h of treatment by CellTiterGlo detection. Results were normalized to dimethyl sulfoxide (DMSO)-treated cells for the same length of time. (C) Effect of CDD-787 and CDD-956 on the cell cycle of MV4;11 and MOLM-13 cells after 24 h of treatment at the IC₅₀. (D) Detection of Annexin V+ cells after 72 h of treatment with CDD-787 and CDD-956. (E) Expression of MYC and GAPDH by RT-qPCR after 8 h of CDD-787 and CDD-956. For all experiments, JQ1 is used as a control. *P < 0.05, **0.001 < P < 0.01, ***0.0001 < P < 0.001, and ****P < 0.0001.